Chimeric Anti-Staphylococcal enterotoxin B antibodies and lovastatin act synergistically to provide in vivo protection against lethal doses of SEB

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Tilahun, Mulualem E ^a,b   Kwan, Alan ^a   Natarajan, Kannan ^d   Quinn, Megan ^a   Tilahun, Ashenafi Y ^c   Xie, Chen ^a   Margulies, David H ^d   Osborne, Barbara A ^b   Goldsby, Richard A ^a,b   Rajagopalan, Govindarajan ^c  

^a AMHERST COLLEGE   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR3 ANTIGEN; MEVINOLIN; STAPHYLOCOCCUS ENTEROTOXIN B; STAPHYLOCOCCUS ENTEROTOXIN B ANTIBODY; TOXIN ANTIBODY; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; ENTEROTOXIN; ENTEROTOXIN B, STAPHYLOCOCCAL; HYPOCHOLESTEROLEMIC AGENT; NEUTRALIZING ANTIBODY; SUPERANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PROTECTION; T LYMPHOCYTE; TOXIC SHOCK SYNDROME; TRANSGENIC MOUSE; ANIMAL; BAGG ALBINO MOUSE; GENETICS; IMMUNOLOGY; MORTALITY; SEPTIC SHOCK; SURVIVAL RATE;

MUS MUSCULUS; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTICHOLESTEREMIC AGENTS; DRUG SYNERGISM; ENTEROTOXINS; HLA-DR3 ANTIGEN; HUMANS; LOVASTATIN; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; SHOCK, SEPTIC; SUPERANTIGENS; SURVIVAL RATE;

EID: 81055144837     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027203     Document Type: Article

References (57)

1. Miethke T, Wahl C, Heeg K, Echtenacher B, Krammer P, et al. (1992) T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J exp Med 175: 91-98.
2. Fraser JD, Proft T, (2008) The bacterial superantigen and superantigen-like proteins. Immunological Reviews 225: 226-243.
3. Herman A, Kappler JW, Marrack P, Pullen AM, (1991) Superantigens: Mechanism of T-Cell Stimulation and Role in Immune Responses. Annual Review of Immunology 9: 745-772.
4. Marrack P, Kappler J, (1990) The staphylococcal enterotoxins and their relatives. Science 248: 705-711.
5. Schlievert PM, (1993) Role of Superantigens in Human Disease. The Journal of Infectious Diseases 167: 997-1002.
6. Bergdoll MS, (1983) Enterotoxins. In: Easom CSF, Adlam C, eds. Staphyloccoi and Staphylococcal Infections. New York: Academic Press, 559-598.
7. Gill DM, (1982) Bacterial toxins: a table of lethal amounts. Microbiol Mol Biol Rev 46: 86-94.
8. Rusnak JM, Kortepeter M, Ulrich RG, Poli M, Boudreau E, (2004) Laboratory Exposures to Staphylococcal Enterotoxin B. Emerging Infectious Diseases 10: 1544-1549.
9. Fraser JD, (1989) High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR. Nature 339: 221-223.
10. Kappler J, Kotzin B, Herron L, Gelfand E, Bigler R, et al. (1989) V beta-specific stimulation of human T cells by staphylococcal toxins. Science 244: 811-813.
11. Marrack P, Blackman M, Kushnir E, Kappler J, (1990) The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells. J exp Med 171: 455-464.
12. Arad G, Hillman D, Levy R, Kaempfer R, (2001) Superantigen antagonist blocks Th1 cytokine gene induction and lethal shock. J Leukoc Biol 69: 921-927.
13. Jupin C, Anderson S, Damais C, Alouf J, Parant M, (1988) Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon. J exp Med 167: 752-761.
14. Petersson K, Forsberg G, Walse B, (2004) Interplay Between Superantigens and Immunoreceptors. Scandinavian Journal of Immunology 59: 345-355.
15. McCormick JK, Yarwood JM, Schlievert PM, (2001) Toxic Shock Syndrome and Bacterial Superantigens: An Update. Annual Review of Microbiology 55: 77-104.
16. Li H, Llera A, Malchiodi EL, Mariuzza RA, (1999) The Structural Basis of T cell Activation by Superantigens. Annual Review of Immunology 17: 435-466.
17. Lowell G, Colleton C, Frost D, Kaminski R, Hughes M, et al. (1996) Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Infect Immun 64: 4686-4693.
18. Lowell G, Kaminski R, Grate S, Hunt R, Charney C, et al. (1996) Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice. Infect Immun 64: 1706-1713.
19. Ulrich RG, Olson MA, Bavari S, (1998) Development of engineered vaccines effective against structurally related bacterial superantigens. Vaccine 16: 1857-1864.
20. Stiles BG, Garza AR, Ulrich RG, Boles JW, (2001) Mucosal Vaccination with Recombinantly Attenuated Staphylococcal Enterotoxin B and Protection in a Murine Model. Infect Immun 69: 2031-2036.
21. Boles JW, Pitt ML M, LeClaire RD, Gibbs PH, Torres E, et al. (2003) Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clinical Immunology 108: 51-59.
22. Visvanathan K, Charles A, Bannan J, Pugach P, Kashfi K, et al. (2001) Inhibition of Bacterial Superantigens by Peptides and Antibodies. Infect Immun 69: 875-884.
23. Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, et al. (2003) Intravenous Immunoglobulin G Therapy in Streptococcal Toxic Shock Syndrome: A European Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases 37: 333-340.
24. Darenberg J, Söderquist B, Henriques Normark B, Norrby-Teglund A, (2004) Differences in Potency of Intravenous Polyspecific Immunoglobulin G against Streptococcal and Staphylococcal Superantigens: Implications for Therapy of Toxic Shock Syndrome. Clinical Infectious Diseases 38: 836-842.
25. Jolles S, Sewell WAC, Misbah SA, (2005) Clinical uses of intravenous immunoglobulin. Clinical & Experimental Immunology 142: 1-11.
26. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, et al. (1999) Intravenous Immunoglobulin Therapy for Streptococcal Toxic Shock Syndrome- A Comparative Observational Study. Clinical Infectious Diseases 28: 800-807.
27. Arad G, Levy R, Hillman D, Kaempfer R, (2000) Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med 6: 414-421.
28. Arad G, Hillman D, Levy R, Kaempfer R, (2004) Broad-spectrum immunity against superantigens is elicited in mice protected from lethal shock by a superantigen antagonist peptide. Immunology Letters 91: 141-145.
29. Lehnert NM, Allen DL, Allen BL, Catasti P, Shiflett PR, et al. (2001) Structure-Based Design of a Bispecific Receptor Mimic That Inhibits T Cell Responses to a Superantigen iochemistry 40: 4222-4228.
30. Hong-Geller E, Möllhoff M, Shiflett PR, Gupta G, (2004) Design of Chimeric Receptor Mimics with Different TCRVβ Isoforms: Type-specific Inhibition of Superantigen Pathogenesis. J biol Chem 279: 5676-5684.
31. Möllhoff M, Zanden HBV, Shiflett PR, Gupta G, (2005) Modeling of receptor mimics that inhibit superantigen pathogenesis. Journal of Molecular Recognition 18: 73-83.
32. Buonpane RA, Churchill HRO, Moza B, Sundberg EJ, Peterson ML, et al. (2007) Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Nat Med 13: 725-729.
33. Tilahun AY, Holz M, Wu T-T, David CS, Rajagopalan G, (2011) Interferon Gamma-Dependent Intestinal Pathology Contributes to the Lethality in Bacterial Superantigen-Induced Toxic Shock Syndrome. PLoS ONE 6: e16764.
34. Tilahun AY, Theuer JE, Patel R, David CS, Rajagopalan G, (2010) Detrimental Effect of the Proteasome Inhibitor, Bortezomib in Bacterial Superantigen- and Lipopolysaccharide-induced Systemic Inflammation. Mol Ther 18: 1143-1154.
35. DaSilva L, Welcher BC, Ulrich RG, Aman MJ, David CS, et al. (2002) Humanlike Immune Response of Human Leukocyte Antigen-DR3 Transgenic Mice to Staphylococcal Enterotoxins: A Novel Model for Superantigen Vaccines. The Journal of Infectious Diseases 185: 1754-1760.
36. Rajagopalan G, Iijima K, Singh M, Kita H, Patel R, et al. (2006) Intranasal Exposure to Bacterial Superantigens Induces Airway Inflammation in HLA Class II Transgenic Mice. Infect Immun 74: 1284-1296.
37. Rajagopalan G, Sen MM, David CS, (2004) In Vitro and In Vivo Evaluation of Staphylococcal Superantigen Peptide Antagonists. Infect Immun 72: 6733-6737.
38. Tilahun AY, Marietta EV, Wu T-T, Patel R, David CS, et al. (2011) Human Leukocyte Antigen Class II Transgenic Mouse Model Unmasks the Significant Extrahepatic Pathology in Toxic Shock Syndrome. The American Journal of Pathology 178: 2760-2773.
39. Silversides J, Lappin E, Ferguson A, (2010) Staphylococcal Toxic Shock Syndrome: Mechanisms and Management. Current Infectious Disease Reports 12: 392-400.
40. Tilahun ME, Rajagopalan G, Shah-Mahoney N, Lawlor RG, Tilahun AY, et al. (2010) Potent Neutralization of SEB by Synergistic Action of Chimeric Antibodies. Infect Immun 78: 2801-2811.
41. Larkin EA, Stiles BG, Ulrich RG, (2010) Inhibition of Toxic Shock by Human Monoclonal Antibodies against Staphylococcal Enterotoxin B. PLoS ONE 5: e13253.
42. Drozdowski B, Zhou Y, Kline B, Spidel J, Chan YY, et al. (2010) Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin B. Journal of Immune Based Therapies and Vaccines 8: 9.
43. Varshney AK, Wang X, Cook E, Dutta K, Scharff MD, et al. (2011) Generation, Characterization, and Epitope Mapping of Neutralizing and Protective Monoclonal Antibodies against Staphylococcal Enterotoxin B-induced Lethal Shock. Journal of Biological Chemistry 286: 9737-9747.
44. Fehr T, Kahlert C, Fierz W, Joller-Jemelka HI, Riesen WF, et al. (2004) Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 175: 83-90.
45. Armitage J, (2007) The safety of statins in clinical practice. The Lancet 370: 1781-1790.
46. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J, (2003) Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 63: 12-23.
47. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, et al. (2006) Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J exp Med 203: 401-412.
48. Jougasaki M, Ichiki T, Takenoshita Y, Setoguchi M, (2010) Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. British Journal of Pharmacology 159: 1294-1303.
49. Roy CJ, Warfield KL, Welcher BC, Gonzales RF, Larsen T, et al. (2005) Human Leukocyte Antigen-DQ8 Transgenic Mice: a Model To Examine the Toxicity of Aerosolized Staphylococcal Enterotoxin B. Infect Immun 73: 2452-2460.
50. Proft T, D. Fraser J, (2003) Bacterial superantigens. Clinical & Experimental Immunology 133: 299-306.
51. Kwak B, Mulhaupt F, Myit S, Mach F, (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399-1402.
52. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, et al. (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7: 687-692.
53. Fischer H, Gjorloff A, Hedlund G, Hedman H, Lundgren E, et al. (1992) Stimulation of human naive and memory T helper cells with bacterial superantigen. Naive CD4+45RA+ T cells require a costimulatory signal mediated through the LFA-1/ICAM-1 pathway. The Journal of Immunology 148: 1993-1998.
54. Fogerty MD, Efron D, Morandi A, Guy JS, Abumrad NN, et al. (2010) Effect of Preinjury Statin Use on Mortality and Septic Shock in Elderly Burn Patients. The Journal of Trauma-Injury Infection & Critical Care 69: 99-103.
55. Klein E, Smith DL, Laxminarayan R, (2007) Hospitalizations and Deaths Caused by Methicillin-Resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 13: 1840-1846.
56. Taneja V, David CS, (1999) HLA class II transgenic mice as models of human diseases. Immunological Reviews 169: 67-79.
57. Taneja V, David CS, (2001) Lessons from animal models for human autoimmune diseases. Nat Immunol 2: 781-784.